Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $384.06 million. The enterprise value is $227.32 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 390.07 million shares outstanding. The number of shares has increased by 8.03% in one year.
| Current Share Class | 390.07M |
| Shares Outstanding | 390.07M |
| Shares Change (YoY) | +8.03% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 33.95% |
| Float | 216.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.50 |
| Forward PS | 4.80 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.19 |
| Quick Ratio | 1.86 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,588.65 |
Financial Efficiency
Return on equity (ROE) is -13.13% and return on invested capital (ROIC) is -12.18%.
| Return on Equity (ROE) | -13.13% |
| Return on Assets (ROA) | -9.88% |
| Return on Invested Capital (ROIC) | -12.18% |
| Return on Capital Employed (ROCE) | -20.31% |
| Weighted Average Cost of Capital (WACC) | 10.93% |
| Revenue Per Employee | $104,317 |
| Profits Per Employee | -$91,560 |
| Employee Count | 818 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | -37.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.56% in the last 52 weeks. The beta is 1.37, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | -16.56% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 36.79 |
| Average Volume (20 Days) | 2,724,281 |
Short Selling Information
The latest short interest is 10.16 million, so 2.60% of the outstanding shares have been sold short.
| Short Interest | 10.16M |
| Short Previous Month | 10.49M |
| Short % of Shares Out | 2.60% |
| Short % of Float | 4.68% |
| Short Ratio (days to cover) | 7.04 |
Income Statement
In the last 12 months, LAB had revenue of $85.33 million and -$74.90 million in losses. Loss per share was -$0.20.
| Revenue | 85.33M |
| Gross Profit | 42.54M |
| Operating Income | -93.31M |
| Pretax Income | -96.70M |
| Net Income | -74.90M |
| EBITDA | -82.33M |
| EBIT | -93.31M |
| Loss Per Share | -$0.20 |
Full Income StatementBalance Sheet
The company has $187.58 million in cash and $30.83 million in debt, with a net cash position of $156.75 million or $0.40 per share.
| Cash & Cash Equivalents | 187.58M |
| Total Debt | 30.83M |
| Net Cash | 156.75M |
| Net Cash Per Share | $0.40 |
| Equity (Book Value) | 424.29M |
| Book Value Per Share | 1.10 |
| Working Capital | 345.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$74.34 million and capital expenditures -$8.30 million, giving a free cash flow of -$82.65 million.
| Operating Cash Flow | -74.34M |
| Capital Expenditures | -8.30M |
| Depreciation & Amortization | 10.98M |
| Net Borrowing | n/a |
| Free Cash Flow | -82.65M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
Gross margin is 49.86%, with operating and profit margins of -109.34% and -87.77%.
| Gross Margin | 49.86% |
| Operating Margin | -109.34% |
| Pretax Margin | -113.33% |
| Profit Margin | -87.77% |
| EBITDA Margin | -96.48% |
| EBIT Margin | -109.34% |
| FCF Margin | n/a |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.03% |
| Shareholder Yield | -8.03% |
| Earnings Yield | -19.50% |
| FCF Yield | -21.52% |
Analyst Forecast
The average price target for LAB is $1.35, which is 37.11% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.35 |
| Price Target Difference | 37.11% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of -0.72 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.72 |
| Piotroski F-Score | 2 |
